Does the media refer more to OCUL or OVID?

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 8 articles in the media. Ocular Therapeutix's average media sentiment score of -0.17 beat Ovid Therapeutics' score of -0.22 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, OVID or VCEL?

Vericel has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ovid Therapeutics $7.25M 61.53 -$17.41M -$0.29 N/A Vericel $292.09M 6.07 $16.52M $0.42 82.71

Is OVID or VCEL more profitable?

Vericel has a net margin of 7.35% compared to Ovid Therapeutics' net margin of -240.11%. Vericel's return on equity of 6.41% beat Ovid Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ovid Therapeutics -240.11% -22.51% -18.67% Vericel 7.35% 6.41% 4.61%

Does the media favor OVID or VCEL?

In the previous week, Ovid Therapeutics had 6 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Ovid Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.93 beat Ovid Therapeutics' score of -0.22 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ovid Therapeutics (OVID) Competitors

$2.39 -0.01 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.41 +0.02 (+1.00%)

As of 07:08 PM Eastern

Compare

OVID vs. NRIX, LKFT, OCUL, VCEL, and HRMY

Should you buy Ovid Therapeutics stock or one of its competitors? MarketBeat compares Ovid Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ovid Therapeutics include Nurix Therapeutics (NRIX), Lakefront Biotherapeutics American Depositary Shares (LKFT), Ocular Therapeutix (OCUL), Vericel (VCEL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

How does Ovid Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Ovid Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	19.06	-$264.46M	-$3.16	N/A
Ovid Therapeutics	$7.25M	61.53	-$17.41M	-$0.29	N/A

Ovid Therapeutics has a net margin of -240.11% compared to Nurix Therapeutics' net margin of -411.37%. Ovid Therapeutics' return on equity of -22.51% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

In the previous week, Ovid Therapeutics had 7 more articles in the media than Nurix Therapeutics. MarketBeat recorded 8 mentions for Ovid Therapeutics and 1 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Ovid Therapeutics' score of -0.22 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Very Positive
Ovid Therapeutics	Neutral

Nurix Therapeutics presently has a consensus price target of $30.46, suggesting a potential upside of 96.78%. Ovid Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 114.44%. Given Ovid Therapeutics' higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Nurix Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

72.2% of Ovid Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ovid Therapeutics beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Ovid Therapeutics (NASDAQ:OVID) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ovid Therapeutics had 4 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 8 mentions for Ovid Therapeutics and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.61 beat Ovid Therapeutics' score of -0.22 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

Ovid Therapeutics currently has a consensus price target of $5.13, indicating a potential upside of 114.44%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, indicating a potential upside of 32.68%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Ovid Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Ovid Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	61.53	-$17.41M	-$0.29	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.44	$363.05M	-$1.41	N/A

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Ovid Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ovid Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	35.19	-$265.94M	-$1.46	N/A
Ovid Therapeutics	$7.25M	61.53	-$17.41M	-$0.29	N/A

Ocular Therapeutix currently has a consensus price target of $23.78, indicating a potential upside of 184.76%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 114.44%. Given Ocular Therapeutix's higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Ovid Therapeutics has a net margin of -240.11% compared to Ocular Therapeutix's net margin of -558.24%. Ovid Therapeutics' return on equity of -22.51% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 8 articles in the media. Ocular Therapeutix's average media sentiment score of -0.17 beat Ovid Therapeutics' score of -0.22 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocular Therapeutix has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Summary

Ovid Therapeutics beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Vericel?

Ovid Therapeutics (NASDAQ:OVID) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

72.2% of Ovid Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ovid Therapeutics presently has a consensus target price of $5.13, indicating a potential upside of 114.44%. Vericel has a consensus target price of $55.40, indicating a potential upside of 59.47%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vericel has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	61.53	-$17.41M	-$0.29	N/A
Vericel	$292.09M	6.07	$16.52M	$0.42	82.71

Vericel has a net margin of 7.35% compared to Ovid Therapeutics' net margin of -240.11%. Vericel's return on equity of 6.41% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Vericel	7.35%	6.41%	4.61%

In the previous week, Ovid Therapeutics had 6 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Ovid Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.93 beat Ovid Therapeutics' score of -0.22 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Vericel has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Summary

Vericel beats Ovid Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Harmony Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Harmony Biosciences has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.14	$158.69M	$2.48	12.93
Ovid Therapeutics	$7.25M	61.53	-$17.41M	-$0.29	N/A

Harmony Biosciences presently has a consensus price target of $40.89, suggesting a potential upside of 27.51%. Ovid Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 114.44%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Harmony Biosciences has a net margin of 16.20% compared to Ovid Therapeutics' net margin of -240.11%. Harmony Biosciences' return on equity of 17.19% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

In the previous week, Ovid Therapeutics had 7 more articles in the media than Harmony Biosciences. MarketBeat recorded 8 mentions for Ovid Therapeutics and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.34 beat Ovid Therapeutics' score of -0.22 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Harmony Biosciences	Positive
Ovid Therapeutics	Neutral

Summary

Harmony Biosciences beats Ovid Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OVID vs. The Competition

Export

Metric	Ovid Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$446.07M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-8.24	17.93	22.30	24.19
Price / Sales	61.53	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	2.39	6.63	9.84	6.72
Net Income	-$17.41M	$24.20M	$3.57B	$337.19M
7 Day Performance	-5.91%	-3.24%	-1.16%	0.48%
1 Month Performance	-14.34%	0.53%	3.85%	5.07%
1 Year Performance	700.13%	47.24%	27.40%	34.25%

Ovid Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OVID Ovid Therapeutics	2.2638 of 5 stars	$2.39 -0.4%	$5.13 +114.4%	+727.9%	$446.07M	$7.25M	N/A	60	News Coverage
NRIX Nurix Therapeutics	2.8828 of 5 stars	$17.75 +1.4%	$30.46 +71.6%	+34.8%	$1.84B	$83.98M	N/A	300
LKFT Lakefront Biotherapeutics American Depositary Shares	2.5724 of 5 stars	$27.58 +0.3%	$36.50 +32.3%	-6.6%	$1.82B	$1.26B	N/A	1,310
OCUL Ocular Therapeutix	2.6963 of 5 stars	$8.22 -0.1%	$23.78 +189.3%	+2.5%	$1.80B	$51.95M	N/A	230
VCEL Vericel	3.2844 of 5 stars	$34.75 +0.1%	$55.40 +59.4%	-14.9%	$1.77B	$276.26M	82.74	300	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OVID) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ovid Therapeutics (OVID) Competitors

OVID vs. NRIX, LKFT, OCUL, VCEL, and HRMY

How does Ovid Therapeutics compare to Nurix Therapeutics?

Summary

How does Ovid Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Ovid Therapeutics compare to Ocular Therapeutix?

Summary

How does Ovid Therapeutics compare to Vericel?

Summary

How does Ovid Therapeutics compare to Harmony Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ovid Therapeutics (OVID) Competitors

OVID vs. NRIX, LKFT, OCUL, VCEL, and HRMY

How does Ovid Therapeutics compare to Nurix Therapeutics?

Which has higher earnings and valuation, NRIX or OVID?

Is NRIX or OVID more profitable?

Does the media prefer NRIX or OVID?

Do analysts recommend NRIX or OVID?

Which has more volatility & risk, NRIX or OVID?

Do institutionals & insiders hold more shares of NRIX or OVID?

Summary

How does Ovid Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Do institutionals and insiders have more ownership in OVID or LKFT?

Does the media favor OVID or LKFT?

Which has more volatility & risk, OVID or LKFT?

Do analysts rate OVID or LKFT?

Which has better earnings & valuation, OVID or LKFT?

Is OVID or LKFT more profitable?

Summary

How does Ovid Therapeutics compare to Ocular Therapeutix?

Do insiders and institutionals have more ownership in OCUL or OVID?

Which has preferable valuation and earnings, OCUL or OVID?

Do analysts recommend OCUL or OVID?

Is OCUL or OVID more profitable?

Does the media refer more to OCUL or OVID?

Which has more risk & volatility, OCUL or OVID?

Summary

How does Ovid Therapeutics compare to Vericel?

Do insiders and institutionals believe in OVID or VCEL?

Do analysts prefer OVID or VCEL?

Which has preferable valuation & earnings, OVID or VCEL?

Is OVID or VCEL more profitable?

Does the media favor OVID or VCEL?

Which has more volatility and risk, OVID or VCEL?

Summary

How does Ovid Therapeutics compare to Harmony Biosciences?

Which has more risk & volatility, HRMY or OVID?

Do institutionals & insiders have more ownership in HRMY or OVID?

Which has higher valuation and earnings, HRMY or OVID?

Do analysts prefer HRMY or OVID?

Is HRMY or OVID more profitable?

Does the media prefer HRMY or OVID?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools